vs
Cheer Holding, Inc.（CHR）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
Cheer Holding, Inc.的季度营收约是MESA LABORATORIES INC的1.1倍（$71.0M vs $65.1M），Cheer Holding, Inc.净利率更高（10.9% vs 5.6%，领先5.3%），MESA LABORATORIES INC同比增速更快（3.6% vs -0.1%）
祺睿控股有限公司是一家多元化控股企业，主要在中国市场运营，核心业务板块覆盖幼儿教育服务、移动生活平台、数字内容供给及面向家庭和企业合作伙伴的整合消费解决方案。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
CHR vs MLAB — 直观对比
营收规模更大
CHR
是对方的1.1倍
$65.1M
营收增速更快
MLAB
高出3.7%
-0.1%
净利率更高
CHR
高出5.3%
5.6%
损益表 — Q2 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $71.0M | $65.1M |
| 净利润 | $7.8M | $3.6M |
| 毛利率 | 70.7% | 64.2% |
| 营业利润率 | 11.7% | 12.2% |
| 净利率 | 10.9% | 5.6% |
| 营收同比 | -0.1% | 3.6% |
| 净利润同比 | -37.5% | 316.6% |
| 每股收益（稀释后） | $0.67 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CHRMLAB
| Q4 25 | — | $65.1M | ||
| Q3 25 | — | $60.7M | ||
| Q2 25 | $71.0M | $59.5M | ||
| Q1 25 | — | $62.1M | ||
| Q4 24 | — | $62.8M | ||
| Q3 24 | — | $57.8M | ||
| Q2 24 | $71.1M | $58.2M | ||
| Q1 24 | — | $58.9M |
净利润CHRMLAB
| Q4 25 | — | $3.6M | ||
| Q3 25 | — | $2.5M | ||
| Q2 25 | $7.8M | $4.7M | ||
| Q1 25 | — | $-7.1M | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | — | $3.4M | ||
| Q2 24 | $12.4M | $3.4M | ||
| Q1 24 | — | $-254.6M |
毛利率CHRMLAB
| Q4 25 | — | 64.2% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | 70.7% | 62.0% | ||
| Q1 25 | — | 61.8% | ||
| Q4 24 | — | 63.3% | ||
| Q3 24 | — | 61.3% | ||
| Q2 24 | 73.4% | 64.0% | ||
| Q1 24 | — | 62.1% |
营业利润率CHRMLAB
| Q4 25 | — | 12.2% | ||
| Q3 25 | — | 7.8% | ||
| Q2 25 | 11.7% | 5.1% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 9.2% | ||
| Q3 24 | — | 6.1% | ||
| Q2 24 | 16.4% | 9.6% | ||
| Q1 24 | — | -460.6% |
净利率CHRMLAB
| Q4 25 | — | 5.6% | ||
| Q3 25 | — | 4.1% | ||
| Q2 25 | 10.9% | 8.0% | ||
| Q1 25 | — | -11.4% | ||
| Q4 24 | — | -2.7% | ||
| Q3 24 | — | 5.9% | ||
| Q2 24 | 17.5% | 5.8% | ||
| Q1 24 | — | -432.2% |
每股收益（稀释后）CHRMLAB
| Q4 25 | — | $0.65 | ||
| Q3 25 | — | $0.45 | ||
| Q2 25 | $0.67 | $0.85 | ||
| Q1 25 | — | $-1.30 | ||
| Q4 24 | — | $-0.31 | ||
| Q3 24 | — | $0.63 | ||
| Q2 24 | $1.23 | $0.62 | ||
| Q1 24 | — | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $29.0M |
| 总债务越低越好 | — | $68.4M |
| 股东权益账面价值 | $322.1M | $186.7M |
| 总资产 | $362.7M | $434.8M |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资CHRMLAB
| Q4 25 | — | $29.0M | ||
| Q3 25 | — | $20.4M | ||
| Q2 25 | — | $21.3M | ||
| Q1 25 | — | $27.3M | ||
| Q4 24 | — | $27.3M | ||
| Q3 24 | — | $24.3M | ||
| Q2 24 | $186.1M | $28.5M | ||
| Q1 24 | — | $28.2M |
总债务CHRMLAB
| Q4 25 | — | $68.4M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | — | $70.3M | ||
| Q1 25 | — | $71.3M | ||
| Q4 24 | — | $72.2M | ||
| Q3 24 | — | $73.1M | ||
| Q2 24 | — | $74.1M | ||
| Q1 24 | — | — |
股东权益CHRMLAB
| Q4 25 | — | $186.7M | ||
| Q3 25 | — | $178.5M | ||
| Q2 25 | $322.1M | $172.5M | ||
| Q1 25 | — | $159.8M | ||
| Q4 24 | — | $155.2M | ||
| Q3 24 | — | $161.5M | ||
| Q2 24 | $286.1M | $150.7M | ||
| Q1 24 | — | $145.4M |
总资产CHRMLAB
| Q4 25 | — | $434.8M | ||
| Q3 25 | — | $430.4M | ||
| Q2 25 | $362.7M | $435.7M | ||
| Q1 25 | — | $433.3M | ||
| Q4 24 | — | $433.3M | ||
| Q3 24 | — | $454.1M | ||
| Q2 24 | $333.2M | $440.4M | ||
| Q1 24 | — | $446.8M |
负债/权益比CHRMLAB
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.9M | $18.8M |
| 自由现金流经营现金流 - 资本支出 | — | $18.0M |
| 自由现金流率自由现金流/营收 | — | 27.7% |
| 资本支出强度资本支出/营收 | — | 1.1% |
| 现金转化率经营现金流/净利润 | 0.51× | 5.17× |
| 过去12个月自由现金流最近4个季度 | — | $37.9M |
8季度趋势，按日历期对齐
经营现金流CHRMLAB
| Q4 25 | — | $18.8M | ||
| Q3 25 | — | $8.2M | ||
| Q2 25 | $3.9M | $1.9M | ||
| Q1 25 | — | $12.7M | ||
| Q4 24 | — | $18.1M | ||
| Q3 24 | — | $5.3M | ||
| Q2 24 | $-6.7M | $10.7M | ||
| Q1 24 | — | $12.9M |
自由现金流CHRMLAB
| Q4 25 | — | $18.0M | ||
| Q3 25 | — | $7.1M | ||
| Q2 25 | — | $884.0K | ||
| Q1 25 | — | $11.9M | ||
| Q4 24 | — | $17.3M | ||
| Q3 24 | — | $3.5M | ||
| Q2 24 | — | $9.9M | ||
| Q1 24 | — | $12.3M |
自由现金流率CHRMLAB
| Q4 25 | — | 27.7% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 19.2% | ||
| Q4 24 | — | 27.6% | ||
| Q3 24 | — | 6.0% | ||
| Q2 24 | — | 16.9% | ||
| Q1 24 | — | 21.0% |
资本支出强度CHRMLAB
| Q4 25 | — | 1.1% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 1.3% | ||
| Q3 24 | — | 3.1% | ||
| Q2 24 | — | 1.5% | ||
| Q1 24 | — | 0.9% |
现金转化率CHRMLAB
| Q4 25 | — | 5.17× | ||
| Q3 25 | — | 3.32× | ||
| Q2 25 | 0.51× | 0.40× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.54× | ||
| Q2 24 | -0.54× | 3.17× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CHR
暂无分部数据
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
